Myocardial Ischemia and Infarction compared to -0.8% and 2.6% in the 5X10 6 cells and controls, respectively. Conclusions: Intracoronary infusion of autologous bone marrow CD34+ cells administered during the repair phase after STEMI, at higher doses than previously given, is safe, and may be associated with improved functional recovery as a result of enhanced perfusion to the peri-infarct zone. 9:30 a.m.
Background: Previous studies evaluating the influence of time-to-reperfusion on infarct size (IS) and myocardial salvage over time in patients with ST-segment elevation myocardial infarction (STEMI) yielded conflicting results. Cardiovascular magnetic resonance (CMR) can visualize areas of irreversible myocardial and microvascular injury (infarct size, IS and microvascular obstruction, MVO, respectively) with late gadolinium enhancement (LGE) imaging and areas of salvaged myocardium at risk with T2-weighted imaging. Methods: Seventy patients with first STEMI, successfully treated with primary PCI within 12 hours from symptom onset, underwent CMR 5±2 days after hospital admission. Patients , patients were subcategorized into 4 quartiles on the basis of pain-to-balloon time distribution: <60 minutes (group A, n= 19), >60 to 150 minutes (group B, n= 17), >150 to 360 minutes (group C, n= 17), and >360 minutes (group D, n= 17). Breath-hold T2-weighted and LGE CMR imaging was used to characterize reversible and irreversible myocardial injury. Results: Shorter time-to-reperfusion (group A) was associated with smaller IS and MVO and larger salvaged myocardium at risk. A progressive increase overtime in IS (8%, 11%, 12%, 18%, p=0.005, respectively), and MVO (0.5%, 1.5%, 3.7%, 6.6%, p=0.039, respectively) was observed, whereas salvaged myocardium at risk suddenly decreases after 60 minutes (8.5%, 3.2%, 2.4%, 2.1%, p =0.003, respectively). Lately reperfused patients (group D) had significantly larger areas of IS and MVO with higher prevalence of intramyocardial hemorrhage compared to group A, with an almost complete disappearance of salvaged myocardium at risk Conclusions: In patients with reperfused STEMI, time-to-reperfusion determines the extent of reversible and irreversible myocardial injury. CMR can identify and quantify areas of salvaged myocardium at risk representing an important tool to be used in large clinical trials assessing different reperfusion strategies. 9:30 a.m.
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Clopidogrel Therapy Following Acute Myocardial Infarction Hospitalization or Stent Insertion: What Are the Consequences of Stopping Therapy Before one Year?
Daniel Wiederkehr, Michelle Krukas, Lee Stern, Lois Lamerato, Dinara Makenbaeva, Essy Mozaffari, John Corbelli, Analytica International, Inc., New York, NY Background: Clopidogrel has been shown to reduce the risk of recurrent acute coronary syndrome (ACS), as reflected by the ACC/AHA guidelines since 2002. Our goal was to evaluate the clinical impact of stopping clopidogrel therapy earlier than one year. Methods: We conducted a retrospective observational cohort study of patients having an acute myocardial infarction (AMI: STEMI or non-STEMI) and/or coronary stent insertion from 2002-07. Patients were enrolled in an integrated commercial health plan which provides care across the continuum of inpatient and outpatient settings. Patients having pharmacy claims indicating less than 30-day supply of clopidogrel were excluded. The occurrence of AMI and/or ACS-related procedures (CABG, PCI with/without stent insertion) was tracked up to one year after initial hospitalization. Multivariate Cox regression using a time-dependent covariate for clopidogrel therapy was used to assess the association between stopping clopidogrel and risk of AMI rehospitalization, ACSrelated procedure, or all-cause mortality while adjusting for demographics, comorbidities, cardiovascular procedures at initial hospitalization, and at follow-up. Results: A total of 1,152 patients had an AMI hospitalization or coronary stent procedure followed by at least 30 days of clopidogrel therapy. Average duration of therapy was 131 days. Seventy-three percent (n=837) of the patients had not refilled their medication routinely for a full year. Stopping clopidogrel was associated with nearly a three-fold increase in the risk of subsequent AMI rehospitalization or ACS procedure (HR 2.71, 95% CI 1.63-4.50). When considering a composite endpoint of all-cause mortality, AMI rehospitalization or ACS procedure, stopping clopidogrel was associated with a two-fold increase in risk (HR: 1.84, 95% CI:1.28-2.65).
Conclusion:
Stopping clopidogrel prior to a full year of therapy following an AMI hospitalization or coronary stent insertion is associated with a significantly increased risk of death, AMI hospitalization, and/or ACS procedure. Healthcare decision makers should consider implementing evidence-based recommendations to minimize patients' risk of recurrent events.
(abciximab 1.56±0.34 vs. tirofiban 1.56±0.37; p=0.9) and at 30-day (abciximab 1.42±0.39 vs. tirofiban 1.42±49; p=0.9). Independent predictors of 30-day LVEF 50% were: preprocedure TIMI-flow >0 (OR=2.4, 95% CI 
TRENDS IN VENTRICULAR SEPTAL RUPTURE AND SURVIVAL

Conclusions:
In this large series of pts with AMI complicated by VSR, the occurrence rate of rupture fluctuated but did not decrease over time. Significantly we observed an increase in the proportion of VSR occurring in subendocardial infarctions. Despite significant increases in the rate of PCI and surgery over time there were no improvements in associated mortality. Surgical repair was found to be associated with reduced shortterm mortality, but the benefit was not maintained long-term. 9:30 a.m. Background: Cell therapy with intracoronary administration of unselected bone marrow cells has been shown to improve LV function in studies. The CD34+ bone marrow population is enriched for endothelial and other progenitors that may contribute to functional improvement by promoting neo-angiogensis and mitigating peri-infarct zone apoptosis. AMR-001 is an ongoing prospective, Phase I multicenter, escalating dose (5, 10, and 15 million CD34+ cells), cohort controlled study, designed primarily to assess the feasibility and safety of isolating autologous bone marrow derived CD34+ cells from patients after STEMI and infusing them into the infarct related artery. Secondary endpoints include assessment of cardiac function using MRI and quantitative resting LV perfusion with SPECT imaging. We hypothesize that CD34+ cell harvest and infusion will be safe and that the improvement in myocardial perfusion and function will be cell dose-dependent. Methods: To date 31 patients (16 treated and 15 controls) have been enrolled and 6-month follow has been completed in the first 2 cohorts. Cell harvest using mini-bone marrow harvest (mean volume 409 ml) under conscious sedation was safe. Adequate numbers of viable Isolex selected CD34+ cells were safely infused via the infarct related artery, 7 to 10 days post STEMI following successful stenting. Results: Compared to baseline, the change in SPECT total severity score and exercise tolerance were both improved in those receiving 10X10 6 cells compared to patients receiving 5X10 6 cells and controls; change in SPECT total severity score of -360, +8, and -62, respectively, p=0.01,10X10 6 vs. others; and change in exercise duration of +3.3, 0.6 and 1.9 minutes, respectively, p=0.05, 10X10 6 vs. others. There was also a non-significant trend to a greater improvement in EF in the higher dose group; 5.8% in the 10X10 6
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